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Chromobacterium violaceum, a saprophyte bacterium
found commonly in soil and water in tropical and subtropi-
cal climates, is a rare cause of severe, often fatal, human
disease. We report 1 confirmed and 2 suspected cases of
C. violaceum septicemia, with 2 fatalities, in siblings after
recreational exposure in northeastern Brazil.
C
hromobacterium violaceum is an aerobic, gram-nega-
tive bacillus usually found as a saprophyte in soil and
water in tropical and subtropical regions (1). Despite ubiq-
uitous distribution, human infection with this organism is
rare. Since the first human case was described in Malaysia
in 1927 (2), <150 human cases have been reported world-
wide, mainly in Asia, the United States, Australia, and
Africa (3–6). Only 3 cases have been reported in South
America, 1 in Argentina (7) and 2 in Brazil (8,9).
Human infection with this organism results in systemic
and severe disease with a high fatality rate (1). C. vio-
laceum  infection may begin with cellulitis and skin
abscesses (10,11), with rapid progression to sepsis and
multiple organ abscesses, predominantly in lungs, liver,
and spleen (3–5). All previous case reports were of indi-
vidual, apparently sporadic infections. We report 1 con-
firmed and 2 suspected cases of systemic C. violaceum
infection in siblings who shared recreational exposure to
stagnant water.
The Study
In May 2004, 3 cases of sepsis syndrome in children
from the same family were reported to the State Health
Secretariat of Bahia in northeastern Brazil. The 3 patients
had contact with soil and stagnant water in a lake in a rural
area of Ilheus municipality, during a day of recreational
activity. The 3 brothers spent several hours swimming in
the lake with other children and adults, including their par-
ents. Sixty persons were in the group.
Fever, headache, and vomiting developed in patient 1, a
previously healthy 14-year-old boy, 2 days after he swam
in the lake. He was examined at a local health service;
amoxicillin was prescribed and he was sent home. Six days
after exposure, he was admitted to a local hospital with
fever, dyspnea, and a cervical abscess. The patient’s
peripheral leukocyte count was 20,000 cells/µL with 5%
bands, 78% neutrophils, 14% lymphocytes, 2%
eosinophils, and 1% monocytes. Hemoglobin was 11.0
g/dL, aspartate aminotransferase (AST) was 225 U/L, and
alanine aminotransferase (ALT) was 120 U/L. Chest
radiograph showed diffuse bilateral consolidation, and an
abdominal ultrasound showed an enlarged liver. Empiric
antimicrobial treatment with oxacillin, ampicillin, and cef-
triaxone was initiated. The patient was transferred to the
intensive care unit and died of septic shock 36 hours after
admission. 
Autopsy showed enlargement of lungs, liver, and
spleen with many abscessed areas of suppurative necrosis.
An extensive bronchopneumonia was also shown. No
spleen lymphoid atrophy was observed. Tracheal aspirate
culture yielded smooth purple colonies on chocolate agar
(Figure 1), identified as C. violaceum by the characteristic
dark purple pigment and biochemical profile.
Antimicrobial drug susceptibility was determined by disk
diffusion. The isolate was resistant to cephalothin, cef-
tazidime, cefoxitin, and ceftriaxone and was sensitive to
trimethoprim-sulfamethoxazole, amikacin, gentamicin,
chloramphenicol, ciprofloxacin, and meropenem. 
Fever and right earache developed in patient 2, a 12-
year-old boy, 3 days after he swam in the lake. He was
examined at a local health clinic and sent home. After
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Figure 1. Colonies of Chromobacterium violaceum on a chocolate
agar plate.2 days, he was admitted to a hospital with purulent dis-
charge in the right ear, fever, facial cellulitis, and diffuse
abdominal pain. Leukocyte count was 1,200 cells/µL with
2% bands, 62% neutrophils, 31% lymphocytes, 1%
eosinophils, and 4% monocytes. Hemoglobin was 8.0
g/dL, with a platelet count of 158,000 cells/µL. Chest radi-
ograph showed diffuse bilateral consolidation. Empiric
treatment with cephalothin and amikacin was initiated, but
the patient’s condition worsened quickly, and he died 6
hours after admission. No cultures were obtained and
autopsy was not performed; therefore, no samples were
available for testing. The patient was considered a suspect-
ed case-patient on the basis of signs and symptoms and
confirmation of the infection in his sibling. 
Vomiting, abdominal pain, and fever developed in
patient 3, a 9-year-old boy, 3 days after he swam in the
lake. Like his brothers, he was treated at a local health clin-
ic and admitted to a hospital 3 days afterwards. Leukocyte
count was 20,500 cells/µL with 4% bands and 82% neu-
trophils. Hemoglobin was 11.5 g/dL, AST was 115 U/L,
and ALT was 26 U/L. Empiric treatment with ceftriaxone,
ampicillin, and metronidazole was initiated. After 48
hours, he was transferred to our institution, the Children’s
Hospital in Salvador, Bahia. On admission, his abdomen
was tender and his liver was enlarged; otherwise, the
results of the physical examination were normal.
Treatment was changed to ceftazidime, oxacillin, and
amikacin. Serial blood cultures were negative for bacteria.
Achest radiograph showed perihilar consolidations in both
lungs. A computed tomographic scan of the abdomen
showed multiple, small liver abscesses (Figure 2). Five
days after admission, the fever continued in the patient,
and cellulitis developed on his left foot and right hand.
Antimicrobial therapy was changed to oxacillin plus
meropenem. The patient became afebrile after 4 days of
meropenem therapy, and symptoms and skin lesions
regressed. Studies to rule out underlying immunodeficien-
cy showed no evidence of glucose 6-phosphate dehydroge-
nase (G6PD) deficiency or HIV infection. The patient
received parenteral antimicrobial drug therapy for 6 weeks
and an additional 4 weeks of trimethoprim-sulfamethoxa-
zole was prescribed at discharge. He had no symptoms
after 3 months of follow-up care and was considered to be
a suspected case-patient on the basis of his symptoms and
confirmation of the infection in his sibling. Results of the
C. violaceum culture from case-patient 1 were reported on
day 6 of hospitalization.
For microbiologic analysis, samples of water and soil
were collected from the lake where the boys had swum. All
6 soil cultures and 4 of 6 water cultures grew C. violaceum.
Soil and water samples collected near the case-patients’
home and neighbors’ homes were negative.
Conclusions
In Brazil, C. violaceum is abundant in the water and on
the borders of the Negro River in the Amazon basin (12);
however, this is >1,000 kilometers from the region where
the cases occurred. C. violaceum infections have been
reported at least twice previously in Brazil. In 1984, the
organism was cultured from skin abscesses of a young man
who had contact with river water in southern Brazil (8). In
2000, it was identified from blood culture in a 30-year-old
male farm worker who died of severe septicemia associat-
ed with multiple lung and liver abscesses (9). Most reports
worldwide have been associated with rural areas (5,8,9) or
stagnant water (6).
This report is the first of a cluster of suspected C. vio-
laceum infections linked to a common source. Systemic
infection caused by C. violaceum is rare but severe and is
associated with fatality rates >60% (1,13). Previous reports
of C. violaceum sepsis have noted fever, hepatic abscesses,
and skin lesions, as observed in this cluster. Facial celluli-
tis and otitis, as observed in patient 2, have also previous-
ly been reported (10). Only our first case was
microbiologically confirmed, but the signs and symptoms
and common epidemiologic exposure suggest that all 3
patients had C. violaceum infection.
Based on the identification of C. violaceum in samples
from the lake and onset of symptoms 2–3 days after expo-
sure, we believe that the 3 siblings were exposed while
swimming and playing on the banks of the lake. One pre-
vious report of 2 cases of C. violaceum pneumonia impli-
cated aspiration of fresh water in near-drowning victims
(6); infection may also have occurred when injured or bro-
ken skin is exposed to stagnant water. No cuts or gross
abrasions on the skin of the siblings were reported, but
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Figure 2. Computed tomographic scan of abdomen of patient 3,
showing multiple, small liver abscesses.microabrasions may have occurred during the recreational
activities. 
Why these siblings, 3 of 60 persons exposed to the
same environment, were the only ones in whom severe ill-
nesses developed is unclear. We hypothesized an underly-
ing factor or familial predisposition to infection.
Previously, underlying defects in host defense, especially
of neutrophils, have been hypothesized to predispose to
infection: cases have been reported in patients with chron-
ic granulomatous disease (13) and G6PD deficiency (14).
However, many case reports describe infections in appar-
ently healthy persons (5). The 1 patient tested in this appar-
ent cluster had no detectable immunodeficiency, and his 2
siblings were apparently previously healthy. 
Despite their cost, carbapenems may be an appropriate
treatment when C. violaceum infection is identified. The
recommended antimicrobial treatment for C. violaceum
infection is not well established; some survivors are treat-
ed with ciprofloxacin, carbapenems, chloramphenicol with
aminoglycoside, or trimethoprim-sulfamethoxazole.
When patient 3 was seen in the late stage of infection,
meropenem was prescribed empirically for presumptive
melioidosis, an infection with Burkholderia pseudomallei
that may begin similarly to cases in this cluster (15). Early
recognition and aggressive antimicrobial drug therapy can
reduce the high mortality rate associated with both C. vio-
laceum infection and melioidosis (1,4,15). Physicians in
tropical and subtropical regions should consider C. vio-
laceum infection as part of the differential diagnosis of
sepsis, especially when associated with skin or multiple
organ abscesses or with a history of exposure to stagnant
water.
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